Ernesto J Munoz

US Patent:

8394614, Mar 12, 2013

Filed:

Jun 4, 2010

Appl. No.:

12/794536

Inventors:

James Roberts - Seattle WA, US
Fred Cross - Seattle WA, US
Paul Warrener - Seattle WA, US
Ernesto Javier Munoz - Seattle WA, US
Martin Henry Lee - Seattle WA, US
Khadidja Romari - Seattle WA, US
Kimberly Marie Kotovic - Seattle WA, US
Jason W. Hickman - Seattle WA, US

Assignee:

Matrix Genetics, LLC - Seattle WA

International Classification:

C12P 5/00
C12P 1/04
C12N 1/22

US Classification:

435170, 435 41, 435243, 4352521

Abstract:

This disclosure describes genetically modified photosynthetic microorganisms, including Cyanobacteria, that contain one or more exogenous genes encoding a diacylglycerol acyltransferase, a phosphatidate phosphatase, and/or an acetyl-CoA carboxylase, and which are capable of producing increased amounts of fatty acids and/or synthesizing triglycerides.

US Patent:

8394621, Mar 12, 2013

Filed:

Oct 23, 2009

Appl. No.:

12/605204

Inventors:

James Roberts - Seattle WA, US
Fred Cross - Seattle WA, US
Paul Warrener - Seattle WA, US
Ernesto Javier Munoz - Seattle WA, US
Martin Henry Lee - Seattle WA, US
Khadidja Romari - Seattle WA, US
Kimberly Marie Kotovic - Seattle WA, US
Jason W. Hickman - Seattle WA, US

Assignee:

Matrix Genetrics, LLC - Seattle WA

International Classification:

C12P 5/00
C12P 1/04
C12N 1/22

US Classification:

4352521, 435 41, 435170, 435243

Abstract:

This disclosure describes genetically modified photosynthetic microorganisms, including Cyanobacteria, that contain one or more exogenous genes encoding a diacylglycerol acyltransferase, a phosphatidate phosphatase, and/or an acetyl-CoA carboxylase, and which are capable of producing increased amounts of fatty acids and/or synthesizing triglycerides.

US Patent:

20130143284, Jun 6, 2013

Filed:

Feb 6, 2013

Appl. No.:

13/761025

Inventors:

MATRIX GENETICS, LLC - Seattle WA, US
Fred Cross - Seattle WA, US
Paul Warrener - Seattle WA, US
Ernesto Javier Munoz - Seattle WA, US
Martin Henry Lee - Seattle WA, US
Khadidja Romari - Seattle WA, US
Kimberly Marie Kotovic - Seattle WA, US
Jason W. Hickman - Seattle WA, US

Assignee:

MATRIX GENETICS, LLC - Seattle WA

International Classification:

C12N 15/79

US Classification:

435134, 4352572, 435477

Abstract:

This disclosure describes genetically modified photosynthetic microorganisms, including Cyanobacteria, that contain one or more exogenous genes encoding a diacyglycerol acyltransferase, a phosphatidate phosphatase, and/or an acetyl-CoA carboxylase, and which are capable of producing increased amounts of fatty acids and/or synthesizing triglycerides.

US Patent:

20130344549, Dec 26, 2013

Filed:

Dec 19, 2011

Appl. No.:

13/995925

Inventors:

James Roberts - Seattle WA, US
Fred Cross - New York NY, US
Margaret Mary McCormick - Seattle WA, US
Ernesto Javier Munoz - Seattle WA, US
Brett K. Kaiser - Seattle WA, US
Michael Carleton - Kirkland WA, US

Assignee:

Targeted Growth, Inc. - Seattle WA

International Classification:

C12P 7/64
C12N 15/82

US Classification:

435134, 4352572, 435471

Abstract:

This disclosure describes genetically modified photosynthetic microorganisms, e.g., Cyanobacteria, that overexpress an acyl carrier protein (ACP), an acyl-ACP synthase (Aas), or both, optionally in combination with one or more overexpressed or exogenous lipid biosynthesis proteins, and/or one or more overexpressed or exogenous glycogen breakdown proteins. Exemplary biosynthesis proteins include diacyglycerol acyltransferases, thioesterases, phosphatidate phosphatases, phospholipases, triacylglycerol (TAG) hydrolases, fatty acyl-CoA synthetases, and/or acetyl-CoA carboxylases, including combinations thereof. Also included are photosynthetic microorganisms comprising mutations or deletions in a glycogen biosynthesis or storage pathway, which accumulate a reduced amount of glycogen under reduced nitrogen conditions as compared to a wild type photosynthetic microorganism. The modified photosynthetic microorganisms provided herein are capable of producing increased amounts of lipids such as fatty acids and/or synthesizing triglycerides.

US Patent:

20180362599, Dec 20, 2018

Filed:

Nov 6, 2015

Appl. No.:

15/525024

Inventors:

- Seattle WA, US
Ernesto J. Munoz - Seattle WA, US

Assignee:

Kineta Chronic Pain, LLC - Seattle WA

International Classification:

C07K 14/435
A61K 47/54
A61K 47/60
A61P 29/00

Abstract:

The present disclosure describes analog conotoxin peptides of the α-conotoxin peptide RgIA. These analog conotoxin peptides block the α9α10 subtype of the nicotinic acetylcholine receptor (nAChR) and can be used for treating pain and inflammation including inflammatory pain, cancer related pain, and neuropathic pain. The RgIA analogs described in the present invention include a variety of sequence modifications and chemical modifications that are introduced to improve the drug-like characteristics of RgIA analogs and thereby increase their therapeutic value.

US Patent:

20160338967, Nov 24, 2016

Filed:

Dec 23, 2014

Appl. No.:

15/107355

Inventors:

- Seattle WA, US
Ernesto J. MUNOZ - Seattle WA, US
James CHESKO - Seattle WA, US
Eric J. TARCHA - Seattle WA, US

Assignee:

KINETA ONE, LLC - Seattle WA

International Classification:

A61K 9/50
A61K 38/17
A61K 47/26
A61K 47/32

Abstract:

Depot formulations including therapeutic proteins are provided. The therapeutic proteins can be toxin-based therapeutic proteins. The depot formulations release the therapeutic protein within sustained effective levels for at least one month following a single administration. The toxin-based therapeutic proteins can include ShK-based proteins.

US Patent:

20160000869, Jan 7, 2016

Filed:

Mar 5, 2014

Appl. No.:

14/772611

Inventors:

- Seattle WA, US
Ernesto J. Munoz - Seattle WA, US

International Classification:

A61K 38/17
G01N 33/50
A61K 47/26
C12Q 1/68
A61K 47/48
A61K 47/02

Abstract:

Disclosed herein are methods of treating immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) comprising administering a toxin-based therapeutic peptide, such as an ShK-based peptide. The peptide can include an acid or amide at the C-terminus and/or the peptide can be attached to an organic or inorganic chemical entity that has an anionic charge.

US Patent:

20150342932, Dec 3, 2015

Filed:

Jun 8, 2015

Appl. No.:

14/733443

Inventors:

- Seattle WA, US
Kristin M. Bedard - Bellevue WA, US
Ernesto J. Munoz - Seattle WA, US
Myra Wang Imanaka - Seattle WA, US
Kerry W. Fowler - Seattle WA, US

International Classification:

A61K 31/429
A61K 31/47
A61K 31/5377

Abstract:

Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.